Research Progress on Pathogenesis of Obesity-Induced Insulin Resistance and Its Therapeutic Targets: PPAR Delta a/ Delta g
Insulin resistance (IR) is defined as a decreased response of peripheral tissues to insulin. It is a common cause of cardiovascular and hepatic diseases, and often precedes the onset of hyperglycemia and predicts the development of type 2 diabetes. Free fatty acids (FFA), inflammation and oxidative...
Gespeichert in:
Veröffentlicht in: | Current signal transduction therapy 2012-05, Vol.7 (2), p.177-184 |
---|---|
Hauptverfasser: | , |
Format: | Artikel |
Sprache: | eng |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 184 |
---|---|
container_issue | 2 |
container_start_page | 177 |
container_title | Current signal transduction therapy |
container_volume | 7 |
creator | Qi, Zhigang Xie, Meilin |
description | Insulin resistance (IR) is defined as a decreased response of peripheral tissues to insulin. It is a common cause of cardiovascular and hepatic diseases, and often precedes the onset of hyperglycemia and predicts the development of type 2 diabetes. Free fatty acids (FFA), inflammation and oxidative stress play key roles in the development and/or progression of IR induced by obesity. Peroxisome proliferator-activated receptors (PPARs) are members of the nuclear hormone receptor superfamily; PPAR agonists can improve IR by regulating glucose and lipid metabolisms, and by inhibiting inflammatory and oxidative stress responses. In the article, we will review the pathogenesis of obesity-induced IR, its therapeutic targets: PPAR Delta *a/ Delta *g, and discuss the signal transduction pathways through which these drugs exert therapeutic effects. |
format | Article |
fullrecord | <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_miscellaneous_1897380741</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1897380741</sourcerecordid><originalsourceid>FETCH-proquest_miscellaneous_18973807413</originalsourceid><addsrcrecordid>eNqVistuwjAQRb2gUunjH2bJJqrzagI7BFRl1SjKPpo6kwcyNnjsBf36phI_0NU99-gsxDLOiyxK35PsUTwxn6TMk0LKpfipiQmdGqFydnDEDNZAhX60Axniaf49fH3P5G_R0XRBUQdHw0FPBuq_wKNRBGhm7RmakRxeKPhJQYNuIM8bqKptDXvSHgHf7jC8iIceNdPrfZ_F6uPQ7D6ji7PXQOzb88SKtEZDNnAbl-siLWWRxek_0l9EhVCn</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1897380741</pqid></control><display><type>article</type><title>Research Progress on Pathogenesis of Obesity-Induced Insulin Resistance and Its Therapeutic Targets: PPAR Delta a/ Delta g</title><source>IngentaConnect Free/Open Access Journals</source><creator>Qi, Zhigang ; Xie, Meilin</creator><creatorcontrib>Qi, Zhigang ; Xie, Meilin</creatorcontrib><description>Insulin resistance (IR) is defined as a decreased response of peripheral tissues to insulin. It is a common cause of cardiovascular and hepatic diseases, and often precedes the onset of hyperglycemia and predicts the development of type 2 diabetes. Free fatty acids (FFA), inflammation and oxidative stress play key roles in the development and/or progression of IR induced by obesity. Peroxisome proliferator-activated receptors (PPARs) are members of the nuclear hormone receptor superfamily; PPAR agonists can improve IR by regulating glucose and lipid metabolisms, and by inhibiting inflammatory and oxidative stress responses. In the article, we will review the pathogenesis of obesity-induced IR, its therapeutic targets: PPAR Delta *a/ Delta *g, and discuss the signal transduction pathways through which these drugs exert therapeutic effects.</description><identifier>ISSN: 1574-3624</identifier><language>eng</language><ispartof>Current signal transduction therapy, 2012-05, Vol.7 (2), p.177-184</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids></links><search><creatorcontrib>Qi, Zhigang</creatorcontrib><creatorcontrib>Xie, Meilin</creatorcontrib><title>Research Progress on Pathogenesis of Obesity-Induced Insulin Resistance and Its Therapeutic Targets: PPAR Delta a/ Delta g</title><title>Current signal transduction therapy</title><description>Insulin resistance (IR) is defined as a decreased response of peripheral tissues to insulin. It is a common cause of cardiovascular and hepatic diseases, and often precedes the onset of hyperglycemia and predicts the development of type 2 diabetes. Free fatty acids (FFA), inflammation and oxidative stress play key roles in the development and/or progression of IR induced by obesity. Peroxisome proliferator-activated receptors (PPARs) are members of the nuclear hormone receptor superfamily; PPAR agonists can improve IR by regulating glucose and lipid metabolisms, and by inhibiting inflammatory and oxidative stress responses. In the article, we will review the pathogenesis of obesity-induced IR, its therapeutic targets: PPAR Delta *a/ Delta *g, and discuss the signal transduction pathways through which these drugs exert therapeutic effects.</description><issn>1574-3624</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><recordid>eNqVistuwjAQRb2gUunjH2bJJqrzagI7BFRl1SjKPpo6kwcyNnjsBf36phI_0NU99-gsxDLOiyxK35PsUTwxn6TMk0LKpfipiQmdGqFydnDEDNZAhX60Axniaf49fH3P5G_R0XRBUQdHw0FPBuq_wKNRBGhm7RmakRxeKPhJQYNuIM8bqKptDXvSHgHf7jC8iIceNdPrfZ_F6uPQ7D6ji7PXQOzb88SKtEZDNnAbl-siLWWRxek_0l9EhVCn</recordid><startdate>20120501</startdate><enddate>20120501</enddate><creator>Qi, Zhigang</creator><creator>Xie, Meilin</creator><scope>7TS</scope></search><sort><creationdate>20120501</creationdate><title>Research Progress on Pathogenesis of Obesity-Induced Insulin Resistance and Its Therapeutic Targets: PPAR Delta a/ Delta g</title><author>Qi, Zhigang ; Xie, Meilin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_miscellaneous_18973807413</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Qi, Zhigang</creatorcontrib><creatorcontrib>Xie, Meilin</creatorcontrib><collection>Physical Education Index</collection><jtitle>Current signal transduction therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Qi, Zhigang</au><au>Xie, Meilin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Research Progress on Pathogenesis of Obesity-Induced Insulin Resistance and Its Therapeutic Targets: PPAR Delta a/ Delta g</atitle><jtitle>Current signal transduction therapy</jtitle><date>2012-05-01</date><risdate>2012</risdate><volume>7</volume><issue>2</issue><spage>177</spage><epage>184</epage><pages>177-184</pages><issn>1574-3624</issn><abstract>Insulin resistance (IR) is defined as a decreased response of peripheral tissues to insulin. It is a common cause of cardiovascular and hepatic diseases, and often precedes the onset of hyperglycemia and predicts the development of type 2 diabetes. Free fatty acids (FFA), inflammation and oxidative stress play key roles in the development and/or progression of IR induced by obesity. Peroxisome proliferator-activated receptors (PPARs) are members of the nuclear hormone receptor superfamily; PPAR agonists can improve IR by regulating glucose and lipid metabolisms, and by inhibiting inflammatory and oxidative stress responses. In the article, we will review the pathogenesis of obesity-induced IR, its therapeutic targets: PPAR Delta *a/ Delta *g, and discuss the signal transduction pathways through which these drugs exert therapeutic effects.</abstract></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1574-3624 |
ispartof | Current signal transduction therapy, 2012-05, Vol.7 (2), p.177-184 |
issn | 1574-3624 |
language | eng |
recordid | cdi_proquest_miscellaneous_1897380741 |
source | IngentaConnect Free/Open Access Journals |
title | Research Progress on Pathogenesis of Obesity-Induced Insulin Resistance and Its Therapeutic Targets: PPAR Delta a/ Delta g |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T09%3A15%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Research%20Progress%20on%20Pathogenesis%20of%20Obesity-Induced%20Insulin%20Resistance%20and%20Its%20Therapeutic%20Targets:%20PPAR%20Delta%20a/%20Delta%20g&rft.jtitle=Current%20signal%20transduction%20therapy&rft.au=Qi,%20Zhigang&rft.date=2012-05-01&rft.volume=7&rft.issue=2&rft.spage=177&rft.epage=184&rft.pages=177-184&rft.issn=1574-3624&rft_id=info:doi/&rft_dat=%3Cproquest%3E1897380741%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1897380741&rft_id=info:pmid/&rfr_iscdi=true |